Surgery still outperforms Ozmpic and other GLP-1 medications

When it comes to weight loss, surgery still prevails. Research shows today that people who undergo obesity surgery tend to lose much more weight than people who take the latest and most effective GLP-1 obesity.

Scientists at New York University conducted the study, which analyzed the real world data from obesity patients. They found that people who received surgery had lost five times over two years on average more than those who described GLP-1. The results also indicate that the GLP-1 drugs are not effective in the real world as they are in clinical trials.

“I think ready -made meals are when you see a new famous medicine that comes out, you have to take it with a grain of salt. I think you have to wait a few years until the real world’s data appears, because it may reduce the results you see in experiments,” a great academic researcher in Noyu,,

Obesity surgery – especially stomach removal and gastric transcendence – is a long time for obesity. People usually lose between 20 % and 30 % of their basic weight after surgery, and often test Long -term improvements In their general health as a result.

But in recent years, the appearance of the most recent GLP-1 drugs such as the Smolotide (the active ingredient in OzemPIC and Wegovy) has greatly changed the field of obesity medicine. These medications are usually more effective (Safe) One of the previous non -surgical obesity treatments, where people lose average between 10 % and 20 % of their weight in clinical trials. They are also linked to Health benefits That extends beyond weight loss.

At first glance, the data suggested that the GLP-1 drugs can approach-or Even bypassingThe effectiveness of obesity surgery. But according to Shababra, there was no strict comparison to the face of these two different types of obesity treatments between patients in the real world.

Chapra and his colleagues examined the unknown medical records of more than 50,000 people who have received surgery (either stomach excision or drifting in the stomach) or GLP-1 treatment (either SMAGLUTIDE or TirzePatide) through the category of factors, others are in health, and the beginning of factors, and others in health health. Patients and weight loss results were tracked for two years.

On average, surgical patients lost 58 lbs (about 24 % of their total weight) by the end of the second year, while the GLP-1 patients on average lost 12 rugs (about 4.7 % of their total weight)-five times. The results were slightly better for people who stayed on their medications for a full year (7 % weight loss) and for those who took Tirzepatide, the latest and most effective GLP-1 available (8 % to 9 %). But the results are still less than the success seen with surgery – not to mention the results of previous clinical trials.

The team’s results were foot This week at the annual meeting of the American Association for metabolic surgery and obesity treatment (ASMBS).

Chapra pointed out that there are several reasons that make these drugs as unsuccessful as they seemed to be in trials. Up to 70 % of the GLP-1 patients stop using it by the first year, for example. Some will stop because the side effects, usually symptoms of the digestive system such as nausea and diarrhea are too much; Others may simply stop because they cannot afford the costs of medicines anymore (the GLP-1 medications are often covered with insurance and can cost more than $ 1,000 a month without coverage). Many GLP-1 patients in their study also did not reach the maximum dose.

Xabra also doubts that many people in the real world do not get the supportive and follow -up care they will get from doctors in a clinical trial. The GLP-1 medications have fueled the growing dimension-for example, in which people are prescribed remotely medications by medical professionals who will not interact with them personally. (Until recently, people can also get vehicle versions of Semaglutide and Tirzepatide, with less safety or effectiveness.)

Researchers do not say that obese people should not take GLP-1, and obesity surgery is not the perfect choice for everyone. Some people may prefer one-time treatment, for example, or they may not have insurance or resources to cover the long-term GLP-1 treatment. Others may be tense about the corridor with any gaseous procedure or have other pre-existing cases that can be held surgery but not the GLP-1 treatment.

At the end of the day, people will need to realize the positives and negatives of these treatments, and those who choose to go with the GLP-1 must manage their expectations, according to Christra.

“They should know that, at least so far in the real world, weight loss will not be what we see with surgery and they also have to know that it is a treatment for life,” he said. “We do not have any protocols for people to keep weight loss as soon as medications stop, so it is important for people to recognize only these facts. I am concerned that many people start medicines without knowing what they really enter.”

The next team plans to take off more data to find out why real life patients are on the same amount of weight as expected.